The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.
Danny Chou, President and Founder at Compassion BioSolution, and Mark Mark Bumiller, Technology Manager at Entegris.Recorded: May 21 2020100 mins
Presented by Danny Chou, President and Founder at Compassion BioSolution, LLC
Followed by an industry perspective presented by Mark Bumiller, Technology Manager at Entegris.
In the past decade, we have witnessed the arrival of a large number of analytical technologies that are useful for characterizing sub-visible particles in protein therapeutics. Even with the diverse tools that are available today, there are still important gaps that have not been filled but yet have a significant role in our ability to fully analyze particles for either product characterization or formulation development purpose. The goal of this presentation is to highlight some of these gaps and share the opportunities that may be captured by new tools that are on the horizon. Finally, the speaker will elaborate on how simultaneous monitoring of sub-micron and micron-sized particles can assist biopharmaceutical formulation development and help fulfill current and future regulatory requirements.”
Full Title: Implementation of Functional Diagnostics and High Throughput Drug Screening of Patient‐Derived Tumor Organoids
Intro / 3D Cell Culture: From Promise to Reality: 00:00 – 6:52
Englander Institute for Precision Medicine Drug Discovery Platform: 6:53 – 10:30
EIPM tumor organoid platform pipeline: 10:31 – 17:28
EIPM organoid types: 17:29 – 18:59
High throughput drug screening Core: 19:00 -23:11
New tools: CRISPR screening: 23:12 – 25:47
Tumor microenvironment: 25:48 – 28:55
Human Cancer Model Initiative / summary: 28:56 – 31:45
Q&A session: 31:46 - 34:59
Precision medicine aims to match individual patients with the best treatment based on the patients’ tumors biologic and molecular characteristics. As part of the Englander Institute for Precision Medicine at Weill Cornell Medical College, the Tumor Organoid Platform is an active program focused on the development of Next Generation Cancer Models derived from metastatic and primary anatomic sites obtained through biopsies, surgical resections and rapid autopsy procedures. With this platform, they are able to extend their personalized medicine program to include high throughput drug screening, which can be validated through genomic sequencing and both in vivo and in vitro models.
Personalized medicine for non-small-cell lung cancer (NSCLC) continues to evolve rapidly, building on a solid diagnostic foundation based on H&E and immunohistochemistry (IHC), incorporating predictive biomarker testing for oncogene-directed therapies and immunotherapies. Understanding the role of biomarker testing, different technologies and latest developments is vitally important for practicing pathologists.
During this Bright TALK webinar, Professor Keith Kerr will review the current diagnostic pathways in lung cancer, outline the role of IHC and molecular testing, differentiate oncogene biomarkers from immunotherapy biomarkers, and share his perspectives on future directions in lung cancer testing, including multiplexed assays.
Dr. Mary C. Brucker, Editor, Nursing for Women's HealthRecorded: May 21 202047 mins
Learn techniques and strategies to publish in Nursing for Women’s Health with editor Dr. Mary C. Brucker. You can expect to learn about developing a manuscript, strategies for getting your work accepted, and common reasons for rejection. During this webinar, Mary will elaborate on what sets Nursing for Women’s Health apart from other journals in this field and the reasons to submit your work to this premium journal. Join this engaging webinar and get an opportunity to also find answers to your questions in the Q&A session during the webinar. You can submit your questions via this link: https://smittalsachdeva.typeform.com/to/lpeD05 and we will aim to answer your questions during the webinar.
Don’t forget to extend this invitation to your colleagues who might find this of interest.
About Nursing for Women’s Health:
Nursing for Women's Health (NWH) is an official journal of the Association of Women’s Health, Obstetric and Neonatal Nurses (AWHONN). The mission of NWH is to improve outcomes for women and newborns through the dissemination of clinical scholarship. The journal focuses on evidence-based practice for women's health, childbearing, and neonatal care. The tone of NWH is practical and reader-friendly while upholding high standards for scholarly content.
NWH publishes a variety of manuscript types, including original research with a clinical focus, reviews, quality improvement projects, practice articles, case reports, continuing nursing education (CNE) articles, health care policy, legislative, or advocacy articles, commentaries, personal essays, and letters to the editor.
Joel Nelson - RF and Microwave Application EngineerRecorded: May 21 202034 mins
What do you do with the result after you take a measurement? Often, people compare the result to a specification and make a “Pass” or “Fail” decision to ship or reject the item under test. They don’t teach you in school how accuracy affects the risk of incorrect Pass/Fail decisions. We will.
Bill Blakely - RF and Microwave Application EngineerRecorded: May 19 202030 mins
This webinar covers CW signal generation and characteristics, including phase-noise and signal synthesis using VCO’s and Phase-Locked-Loops.It will also discuss analog and digital modulation generation and measurement techniques.
Marc Hurlbert; Tom WilliamsRecorded: May 19 202060 mins
The landscape for melanoma research and treatment has rapidly changed over the last decade. Since 2011, the FDA has approved 12 new melanoma treatment regimens – including new classes of drugs that are molecularly targeted therapies (BRAF/MEK inhibitors), immune checkpoint inhibitors (anti CTLA-4, PD-1/PD-L1) and other immunotherapies (e.g. T-Vec). Scientists have also unraveled many of the genomic mutations found in the most common form, cutaneous melanoma, melanoma that arises primarily on sun-exposed areas of the skin. With these advances in research and treatment, the key unanswered questions have changed rapidly and existing preclinical models may not be sufficient to answer such questions surrounding immune checkpoint inhibition; resistance development, comparing to cuaneous melanoma, and how to improve early detection.
Importantly, there are no models that accurately predict the patient journey. New models and additional research is needed to more fully represent all melanoma subtypes, stages, or treatment responses.
About the speakers:
Marc Hurlbert, Ph.D. Chief Science Officer, Melanoma Research Alliance. Marc is currently responsible for guiding MRA’s scientific strategy, overseeing the peer-reviewed grant-making program, and forging scientific collaborations. He has more than 18 years of nonprofit and grant-making experience focused on advancing medical research. Past work has included treatment and prevention strategies for breast cancer, lymphoma and multiple myeloma, as well as juvenile diabetes.
Tom Williams, PhD, Life Sciences Professional Services Project Manager, Elsevier. Tom is a Life Sciences Knowledge Manager and Research Scientist. with extensive experience as an academic researcher in neurodegeneration and Alzheimer’s disease. He is also in skilled biophysical chemistry, dementia disorders, and biochemistry; and the author of many publications in the field of Alzheimer’s disease.
Biba Visnjicki, MD, Fraunhofer Project Center & Thomas Vollmer, Head of Production Quality Dept, Fraunhofer IPTRecorded: May 19 202059 mins
Businesses are currently facing many challenges, including the need to work towards attaining an Industry 4.0 standard. Industry 4.0 is all about optimization; from managing big data to efficiency in the production line. All this aims at enabling businesses to make quicker, smarter decisions while minimizing costs. This webinar sets out to explain the challenges and to offer solutions in the adoption of I4.0 related technologies.
Lawrence De Belder, Senior Principal Engineer at j&J and Bob Lenich, Director of Life Sciences Business at EmersonRecorded: May 19 202099 mins
Presented by Lawrence De Belder, Senior Principal Engineer Continuous Manufacturing at Johnson and Johnson
Followed by an Industry Perspective presented by Bob Lenich, Director of Life Sciences Business at Emerson
The counter is at Six today: Orkambi, Symdeko, Trikafta (Vertex); Prezista (Johnson and Johnson); Verzenio (Eli Lilly); Daurismo (Pfizer) –are all approved by the FDA – Johnson and Johnson’s Tramacet for the Japanese market not included. Several large Pharma companies have chosen the path of Continuous Manufacturing, and announced they will use this platform as their default for development and consequently – commercial manufacturing of their Oral Solid dose drug product pipeline.
During this webinar, the author will explain the consequences of this decision, and different strategies to handle a pipeline that can be highly dynamic. Different techniques will be discussed that can be used to bring products with bad flow properties into a continuous process. Impact of different equipment in development, clinical and commercial environment will be detailed out, and mitigations will be proposed to overcome these differences. All will be placed in front of a background of regulatory requirements, changing market demand, and evolving strategies of equipment vendors.
Vaccines are considered to be one of the biggest public health achievements of the past century. Vaccines act by initiating the innate immune response when activating antigen presenting cells, inducing a protective response towards a pathogen. These agents may contain live attenuated, inactivated, or only parts of a pathogen.
Corning provides diverse single-use products for upstream vaccine manufacturing needs reducing the cost and minimizing the labor per titer.
This webinar provides background information about the main forms of vaccine design, R&D, and manufacturing workflows, data generated in Corning’s application labs and vaccine considerations for COVID-19.
Frances Sexton, Carsten Worsøe, Ken Wong, and Satish Kumar MohanveluRecorded: May 18 2020104 mins
Since the first publication of Biophorum (previously known as BPOG) Extractable Testing Recommendation in 2014, the combined team of end-users and suppliers has collaborated to examine all improvement opportunities to the original extractable testing recommendation since 2017. During this webinar, the presenters will highlight all the changes to the final revised version of Biophorum Extractable Testing Recommendation. Specifically, the output of a data review of 26 extractable data sets spanning wide varieties of single use components, which has led to the changes to be made in the original recommendation, will be presented.
The revised extractable testing recommendation will be presented to highlight:
1 End-users and suppliers collaboration set up;
2 Specific updates to the extraction study recommendation;
3 Specific areas of flexibility when implementing the protocol;
4 Updates to the analytical test method system suitability;
To facilitate a harmonized extractable data reporting to end users, the presenters will introduce the newly designed Biophorum Extractable Data Summary (BEDS) template. Some levels of details with regards to what specific information or format of templates are compulsory and what are flexible for supplier to tailor to their own preferences will be detailed during the webinar. How end users can gain access to these extractable summary reports from suppliers, including subsuppliers, will be addressed.
Additionally, several FAQs questions will be presented to clarify some common questions. The webinars will end with 30 minutes of a panel discussion for participants to seek clarify of all presented information.
Brian McKellar, Edge Computing Expert, Keysight TechnologiesRecorded: May 15 202053 mins
Are your collaboration, voice, and video applications struggling to keep up with an influx of remote connections? It’s hard to perform at your best if your network isn’t performing at its best. You need to focus on business — not whether the next conference call is going to work.
Join this webinar and discover how active network monitoring can help you minimize service disruptions and get back on track. You will learn how to:
-verify network readiness for unexpected events, like a significant increase in teleworking users and VPN load
-validate quality of experience, troubleshoot bottlenecks, and pinpoint where to increase bandwidth or adjust network quality of service
-troubleshoot faster by identifying whether performance issues stem from your network, your carrier, your applications, or your users’ connection
Wayne Arvidson, Director, Global Edge Partner and Industries Office, Safety and Security | Computer VisionRecorded: May 14 202030 mins
In today’s world of Digital Transformation, Safety and Security | Computer Vision capabilities are front and center. Whether it’s edge computing, artificial intelligence and machine learning at the edge, core or cloud, see how your organization can deploy next generation safety and security solutions.
Join Wayne Arvidson, Director, Global Edge Partner and Industries Office, Safety and Security | Computer Vision, Dell Technologies for this live webinar.
What’s in It for You
•Gain insights into industry trends and game changers driven by a dynamic community.
•Explore emerging safety and security use cases and learn how Dell and our partners make them real today.
•Hear how Dell Technologies brings together different partners and input from the community to improve and design new solutions.
Joel Nelson - RF and Microwave Application EngineerRecorded: May 14 202056 mins
During this session we will cover swept tuned and FFT receiver techniques and the optimization of spectral search techniques including RBW, VBW and dynamic range criteria for the most accurate measurements. Distortion and noise contributions are described as well.
Andrew Teasdale, Senior Principal Scientist at AstraZeneca and Piet Christieans, Phd,Scientific Director at Nelson LabsRecorded: May 14 202094 mins
FULL TITLE: Assessing the Risk of Interaction Between Extractables and Leachable and Therapeutic Proteins
Presented by Andrew Teasdale, Senior Principal Scientist Impurity management and External Advocacy at AstraZeneca
Biologics and Peptides often present their own challenges in respect to leachables. They are typically administered parenterally and therefore there is a high risk of interaction between dosage form and packaging / administration system. They are often low dose and sensitive to structural modifications, this can impact Safety (immunogenicity), Quality (instability, aggregation) and Efficacy (loss of potency). This webinar will examine the potential risk factors through case study examples including reactive leachables, the impact of sterilisation and adverse events and their route cause. It will conclude by looking at opportunities to look predictively at potential issues and how this can be incorporated into product design
Followed by Piet Christieans, Phd,Scientific Director at Nelson Labs
Amy Wesa, PhD, Director of Immuno-Oncology Research, Champions OncologyRecorded: May 14 202035 mins
Hematological malignancies are cancers that begin in the cells of blood-forming tissue or in the cells of the immune system. These types of cancer, specifically, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and Multiple Myeloma (MM) are on the rise in the aging population globally. In this webinar, Dr. Wesa will demonstrate how patient-derived hematologic malignancy in vivo and ex vivo models can be used to advance drug development.
Viewing this webinar will help you to:
•Develop an understanding of a robust approach to human AML Patient-derived Xenograft (PDX) in vivo models
•Learn how to select study endpoints for in vivo and ex vivo models
•Learn how to advance early stage compounds through Champions’ hematologic Vitroscreen for AML, B-ALL and MCL Disease indications
Dr. Lewis Collins, Editor-in-Chief, One Earth (A Cell Press journal)Recorded: May 14 202076 mins
Learn techniques and strategies for publishing in transformative ground-breaking journals with Dr. Lewis Collins, Editor-in-Chief of One Earth (a Cell Press journal). Dr. Collins will share tips on developing your papers for ground-breaking publications, elaborate on his experience of working with researchers and authors throughout the research publishing cycle and the opportunity to broadly disseminate findings. Dr. Collins will also share more details about the growth of Cell Press journals in the physical and environmental sciences field, including the launch of many new titles such as Chem, Matter, Joule, and One Earth. He’ll outline Cell Press’ approach to high-demand, multi-disciplinary content, and expanding OA publishing strategies at Cell Press. Join this engaging webinar to find the answers to your pressing questions in the Q&A session during the webinar. Don’t forget to extend this invite to your colleagues who might find this of interest.
About Lewis Collins:
Inspired by David Attenborough documentaries as a child, Lewis has been amazed by the natural world from an early age. While undergraduate and master’s degrees in Earth science (Cardiff University), and Climate Change (University of East Anglia) nurtured this interest, it was doctoral (British Antarctic Survey) and post-doctoral (Université Pierre et Marie Curie) research on Antarctica that centered his focus on environmental change. Prior to launching One Earth, Lewis spent over 5 years with Nature Communications, where he led the Earth editorial team and curated, commissioned, handled (and occasionally rejected…) research across the full spectrum of Earth and environmental science. Lewis is particularly interested in grand challenges associated with land-use and the competing demands for this increasingly scarce resource.
Tony Wade- SR. Application EngineerRecorded: May 12 202077 mins
Transmit/receive signal chains will be introduced along with important characteristics for design and measurement that will be discussed throughout the RF Back to Basics 5 session series. The Network Analysis section will cover transmission line basics, S-Parameters, and the Smith Chart. Transmit, receive and directivity paths will be described along with how dynamic range and accuracy can be optimized. Calibration and error correction will also be covered.
Mikkel Nissum, Vaccine R&D Quality Site Lead at GSK VaccinesRecorded: May 12 202046 mins
Presented by Mikkel Nissum, Vaccine R&D Quality Site Lead at GSK Vaccines
Only clean drinking water rivals vaccination in its ability to save lives. Yet, development and manufacturing of vaccines remain challenging. Vaccines comprise a heterogeneous variety of targets. Each target requires a dedicated development and manufacturing process adding to the timelines for getting new vaccines to the patient and to ensure a reliable supply. For the downstream processing part, often the process is composed of an optimized set of up to three chromatographic steps to provide the final desired quality of the target. On top of the long development time required to develop such a multi-step process, at times, the end result may not be satisfactory, in particular regarding purity of the target.
In order to overcome this downstream processing challenge, we embarked on establishing a purification platform based on affinity purification. The main advantages of such a platform for vaccine manufacturing would be:
1)By applying a positive selection principle for chromatography, the number of chromatographic steps may be reduced to just one step
2)Establishing a platform would require minimal process changes from one target to another
3)Downstream processing would become predicable in terms of development time and costs
The journey of establishing the affinity purification platform focusing on main challenges and key results will be presented in the Webinar.
Dr. Liza Kunz and Jen Kaplan, LCGCRecorded: May 12 202057 mins
Cell-free DNA prenatal test menus have rapidly expanded in recent years to address not only the common trisomies, but also sex chromosome aneuploidies, copy number variants, and rare autosomal trisomies. However, “more” is not necessarily “better”. Potential benefits to patients must be carefully weighed against potential harms before tests are introduced into clinical practice. Please join us for an in-depth examination of clinical considerations and implications of expanded cfDNA test menus.
Kavitha Scranton, Ph.D., Senior Scientific Editor, Immunity (Cell Press)Recorded: May 12 202079 mins
Would you like to learn tips for writing and developing a strong narrative for your work? Do you want advice on how to prepare your manuscripts for publication in the best journal for your research? Join us for a webinar with Kavitha Scranton, Ph.D., Senior Scientific Editor at Immunity (Cell Press) to learn techniques and strategies to set yourself up for publishing success. Kavitha will share tips on developing your manuscript (with a special focus on researchers based in the Turkey/ME region), elaborate on her experience working with researchers throughout the publishing cycle, and highlight opportunities to broadly disseminate your research findings. Kavitha will also share more details about the growth of multidisciplinary Cell Press journals. Join this engaging webinar and get answers to your questions in the Q&A session. Don’t forget to extend this invitation to your colleagues who might find this of interest.
About Kavitha Scranton:
Kavitha Scranton received her Ph.D. in Immunology from the University of Massachusetts Medical School, where she studied the development and function of γδ T cells in the laboratory of Dr. Joonsoo Kang. She conducted her postdoctoral research at the Broad Institute of MIT and Harvard on T cell-mediated autoimmunity in the laboratory of Dr. Ramnik Xavier. In 2015, Kavitha joined Immunity as a scientific editor.
Moderated by Prof Ian Gibson, Scientific Director, Fraunhofer Project CentreMay 26 202010:00 amUTC60 mins
The session will give insight into the current state of industrial additive manufacturing. Highlighting the potential for big corporates and small-medium enterprises and sharing examples of companies that have been able to incorporate additive manufacturing in their existing set-up. But we will also hear what the main challenges and obstacles are. How can a company properly assess whether they are ready for additive manufacturing? What are the most common assumptions and do they prove to be correct? And what do the experts see further down the road, what do they expect in terms of adoption and development of both hardware and materials in the coming 5-10 years?
Frances Arnold, Lutz Ackermann, Corinna Schindler, and Douglas W. StephanMay 26 20202:00 pmUTC105 mins
The field of catalysis in chemistry was historically dominated by the use of transition metal catalysts. Due to a unique set of properties, precious metals in particular have played an integral role in developing catalysts for new modes of chemical bond activation and formation. One major and inherent drawback of precious metals, however, is their scarcity; in order to transition chemistry to a more sustainable use of the world’s limited resources, finding alternative strategies for catalysis is a major driving force in contemporary research. In this spirit, this webinar will feature talks about four areas of sustainable catalysis from leaders in their respective fields, highlighting state-of-the-art approaches and providing guidance for future developments in these areas of research.
Frances Arnold is Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry, and Director of the Donna and Benjamin M. Rosen Bioengineering Center at Caltech. She received the Nobel Prize in Chemistry in 2018 for directed enzyme evolution.
Lutz Ackermann is a Professor at the Georg-August-University Göttingen. The development and application of novel concepts for sustainable catalysis constitutes his major current research interest, and he has a topical focus on C–H activation.
Corinna Schindler is an Associate Professor at the University of Michigan. The research interests of her laboratory include the synthesis of complex molecules and the development of new synthetic transformations between carbonyls and alkenes.
Douglas W. Stephan is a Professor at the University of Toronto and a world-leading researcher in inorganic chemistry/catalysis and the founder of the field of “frustrated Lewis pair” (FLP) chemistry. He has received many national and international awards, including Humboldt and Killam Fellowships.
Systems thinking has become an essential part of modern medicinal chemistry and new drug development (1). Dealing with the increasing data volumes, information silos and low interoperability has become one of the biggest challenges to medicinal chemists when trying to take a holistic approach to identify the interactions and hidden connections within the organelles, cells, tissues, organisms. Often, we wonder:
“Am I seeing the big picture without losing insight of the details?”
In this webinar, we will discuss how to take a system approach to create new chemistry knowledge, to translate knowledge into useful applications and finally to be ready to face the unfolding world crises (2). The topics include
- Systematic integration of biological and chemical data;
- AI-ready data for synthesis route design and prediction;
- Three practical examples using system thinking examples, including
1. digitalization of chemistry knowledge in pharmaceutical industry,
2. responding to COVID-19 pandemic using conscientious data excerption from literature,
3. data readiness in green chemistry to support sustainability.
Change management and education are inevitably critical to pursuing systems thinking approach, therefore we will talk about some best practices for pharmaceutical industry and educational system based on our learning's from the collaborative projects.
(1) Systems Thinking for Medicinal Chemists, Jacobs Journal of Medicinal Chemistry, 2015, I (1),004
(2) One-world chemistry and systems thinking, Nature Chemistry, 2016, 8, 393–398
Paul Dockerty, PhD, is a Customer Engagement Manager in the Professional Services group at Elsevier, now responsible for supporting pharmaceutical customers in their digitalization journey. He is passionate about using data as a leverage to fight the natural resistance to change in digital transformations.
Lea Nienhaus, Raffaella Buonsanti, and Bozhi TianMay 27 20202:00 pmUTC120 mins
The interactions between light and matter have been widely studied for applications in energy, bioelectronics, and catalysis, among others. These applications are heavily reliant on precise synthesis and materials characterization in order to fundamentally understand the physics, chemistry, and biology that drive the observed phenomena.
In this webinar, Lea Nienhaus, Raffaella Buonsanti, and Bozhi Tian discuss their efforts in studying light/matter interactions from different disciplinary backgrounds. In addition to their scientific insights, they will speak about their ongoing broader engagement with the scientific community and strong advocacy for mentoring, outreach, and science communication. Specifically, during a panel discussion, they will address how they have tried to keep engaged during this time away from the lab.
About the speakers:
Lea Nienhaus, Assistant Professor, Florida State University
Lea Nienhaus obtained her PhD from the University of Illinois at Urbana-Champaign. Since 2018, the Nienhaus group has pioneered the application of bulk perovskite sensitizers in photon upconversion, and they are currently working on unraveling the complex photophysical processes occurring in these devices.
Raffaella Buonsanti, Assistant Professor, EPFL
Raffaella Buonsanti started her position as Tenure Track Assistant Professor at the Institute of Chemical Sciences and Engineering (ISIC) of the École Polytechnique Fédérale de Lausanne (EPFL) in November 2015. Through their core expertise in colloidal synthesis, her team develops novel approaches to creating complex materials to drive chemical transformations.
Bozhi Tian, Associate Professor, University of Chicago
Bozhi Tian received his Ph.D. degree in physical chemistry from Harvard University in 2010. He is currently an associate professor at the University of Chicago and working on semiconductor-enabled fundamental studies of subcellular biophysics and soft matter dynamics.
Pegah Alavi - Sr. Application EngineerMay 27 20203:00 pmUTC46 mins
This webinar introduces Keysight’s Advanced Design System (ADS) and covers linear design techniques including S-parameter simulation, impedance matching, tuning, and optimization. It also touches on non-linear frequency- and time-domain simulation, EM Simulation, and passive and active RF device models.
Dr Toni Drescher, Dr Biba Visnjicki & Mr Eddy van HijumMay 28 20207:00 amUTC60 mins
The lack of supplies undermines the entire global effort to stop the spread of COVID-19. Fraunhofer Project Center together with KEX Knowledge Exchange are working together to act as a stable supply chain for protective equipment to Dutch industries
During this forum, we will be discussing
- Why we are pushing this initiative and what challenges we are facing?
- What exactly we are offering to support medical stations and companies
- How does the process work and how this gives value to the Netherlands?
- Dr. Toni Drescher; KEX Knowledge Exchange AG; CEO
- Dr. Biba Visnjicki; Fraunhofer Project Center; Managing Director
- Mr Eddy van Hijum; Deputy at the Province of Overijssel and member of the European Committee of the regions
Chelsea Riveley, MBA, Head of Business Development, Flow Cytometry ServicesMay 28 20201:00 pmUTC60 mins
This webinar provides an overview of flow cytometry and its potential uses in the regulatory setting. Two case studies will be presented to detail the unique aspects of conducting flow cytometry in both a preclinical and clinical regulated setting. The following phases of developing and validating a robust and reliable flow cytometry assay will be illustrated in this webinar: The critical steps to any flow cytometry assay – panel design, assay development, descriptions of validation test scripts that should be conducted along with suitable acceptance criteria, proper instrument set-up and appropriate controls, gating strategy and identification of cell subsets, and correct interpretation of flow cytometry data. Lastly, what to look for when choosing an outsourcing partner for flow cytometry will be discussed. These include some of the key decision points and factors to consider such as expertise, regulatory requirements, logistics, timelines, and price.
Michael Knight, Global CTO, Safety and Security – Industry Edge, Dell TechnologiesMay 28 20203:00 pmUTC30 mins
Welcome back to Dell Technologies Innovation Webinar Series. In this conversation we will explore and focus on the “Modern Uses of Thermal Imaging and Computer Vision Technologies”. The next generation of safety and security solutions such as thermal imaging and computer vision are being used in novel ways in today’s world, and we believe this is only the beginning.
Kelsey Hatzell, Yifei Mo, and Nella Vargas-BarbosaMay 28 20203:00 pmUTC105 mins
The importance of more than 40 years of research on lithium-ion batteries was recognized with the 2019 Nobel Prize in Chemistry. As the world is moving toward electrification and the greater use of renewable energy, the question that researchers have been looking to answer is what is the next lithium-ion battery? In this session, three early career researchers who are helping to shape the future of battery research will provide their perspectives on solid-state batteries. The talks will address crucial aspects of developing solid-state batteries, ranging from materials discovery to operando characterization. This webinar aims to highlight innovative work that has the potential to shape the direction of future battery research and development.
About the speakers:
Kelsey Hatzell is an assistant professor in mechanical and chemical engineering at Vanderbilt University, Nashville, USA. Her research group focuses on understanding transport at solid|solid and solid|liquid interfaces for a range of applications related to energy storage, conversion, and separations applications.
Yifei Mo is an associate professor of materials science and engineering at the University of Maryland, College Park, USA. Dr. Mo’s research aims to advance the understanding, design, and discovery of engineering materials through cutting-edge computational techniques, with current emphases on new materials for energy storage and conversion.
Since January 2019, Nella Vargas-Barbosa is a junior group leader in the nanochemistry department at the Max Planck Institute for Solid State Research in Stuttgart, Germany. Her research interests focus on the electrochemical characterization of interfaces with applications in energy storage and conversion.
Dr. Patricia Robin McCartney, Associate Editor, Journal of Obstetric, Gynecologic & Neonatal NursingMay 28 20204:00 pmUTC45 mins
Learn more about the Journal of Obstetric, Gynecologic & Neonatal Nursing from Dr. Patricia Robin McCartney, Associate Editor. In this engaging webinar, Dr. McCartney will share information about JOGNN, the JOGNN audience, and what to consider before submitting your manuscript for publication consideration in JOGNN. You will learn about the criteria for reporting clinical projects in manuscripts for the Health Care Improvement and Evaluation category. Dr. McCartney will also provide advice on preparing your manuscript, editorial style, the publishing process, and resources available to support authors.
This webinar includes the opportunity to ask questions during the Q&A session. Don’t forget to extend the invite to your colleagues and friends who may find this of interest.
You can also submit your questions via this link: https://smittalsachdeva.typeform.com/to/lpeD05
About JOGNN (Journal of Obstetric, Gynecologic & Neonatal Nursing):
JOGNN is an official journal of the Association of Women’s Health, Obstetric and Neonatal Nurses, and a premier resource to advance the health and health care of women, childbearing families, and newborns through the publication of peer-reviewed nursing and interdisciplinary scholarship. With a focus on nursing practice, JOGNN publishes the latest research, reviews, methods, clinical projects, practice issues, case reports, commentaries, resources for evidence-based practice, and policies related to the care of women, childbearing families, and newborns. This peer-reviewed scientific and technical journal is highly respected for groundbreaking articles on important - and sometimes controversial - issues. Articles published in JOGNN emphasize research evidence and clinical practice, building both science and clinical applications. JOGNN seeks research and clinical manuscripts on the evidence supporting current best practice as well as developing or emerging practice trends.
Lisa Gervais, Fiona PattisonMay 28 20204:00 pmUTC60 mins
In this 60 minute webinar presented by Elsevier staff, you will learn how to get started using Elsa. We’ll guide you through how to navigate Elsa, use the document editor, collaborate on your chapters, and how to send your chapters through the workflow. Plus, a Q&A portion so you can get help in areas not covered in the agenda.
Dan Hill, Manufacturing Scientist at BiogenJun 3 20202:00 pmUTC105 mins
Full Title:Advanced Raman Spectroscopy Beyond In-Process Glucose Control of Commercial Cell Culture Processes
Presented by Dan Hill, Manufacturing Scientist at Biogen
The use of in-line Raman spectroscopy as an in-line process analytical technology (PAT), in the biotechnology industry, has matured over the past decade from a technology with promise to a standard tool for real-time, continuous monitoring of cell culture processes. There is an ever-growing body of work demonstrating successful application from metabolite and product quality monitoring to process control in both process development and GMP manufacturing environments. This is due, in part, to advances in technology robustness, user- and integration-interfaces, improved sensitivity, and fluorescence rejection. Organizations are now faced with the difficult task of best leveraging these tools and extracting the most value from them. Thus, defining and executing Raman program strategy is critical to the technology’s long-term success and sustainability.
This presentation will describe Biogen’s past efforts and strategic direction as it relates to in-line Raman spectroscopy for cell culture operations and how we intend to leverage its capability beyond metabolite monitoring and glucose feedback control to become an essential element of our Advanced Process Control efforts.
About the Presenter:
Hilary Sherman is a Senior Scientist in the Corning Life Sciences Applications Lab located in Kennebunk, ME. Hilary has been with Corning Incorporated since 2005 and has worked with a wide variety of cell types including mammalian, insect, primary, stem cells and organoids in a vast array of applications. Her key roles at Corning involve creating technical documents such as protocols and whitepapers as well as providing technical support and training for both the Corning sales force and customers. Hilary received her B.S. degree in Biology from the University of New Hampshire. In the last several years, Hilary has focused on 3D cell culture applications including human organoid culture
Heather Van Epps, Editor-in-Chief The Lancet RheumatologyJun 4 20203:00 pmUTC69 mins
Hear Heather Van Epps, Editor-in-Chief of The Lancet Rheumatology, to learn about techniques and strategies for preparing your paper to submit to high-impact journals.
Heather shares her experiences working with researchers and authors throughout the research publishing cycle. You can expect to learn about how to develop papers for submission to publications like the Lancet family of journals.
Due to high engagement, we're making the webinar recording available to you. And don't forget to download your manuscript checklist from the resources section.
Amy Wesa, PhD, Director of Immuno-Oncology Research at Champions OncologyJun 8 20209:00 pmUTC55 mins
To develop the most successful novel agents for cancer, researchers require preclinical models that fundamentally epitomize patient populations to enable predictive outcomes. Patient-derived models represent a considerable advantage over traditional models of cancer to expedite drug development. In this webinar, Amy Wesa, PhD, of Champions Oncology Inc, will discuss how complementing these translational PDX models with the introduction of human immune cells is driving the next generation of patient-derived models. View this webinar to learn: The latest advances in human immune system mouse models for oncology therapeutics The power of primary patient-derived models for acute myeloid leukemia (AML) Novel methods for evaluating natural killer (NK) cell therapeutics of cancer in humanized mice
While all types of literature review are becoming reasonably more attractive for students, researchers, practitioners and policy makers the workload involved in all types of evidence synthesis should not be underestimated. Apart from standardization of procedures and methods, many organizations and collaborations started using computers to reduce the workload and save time in processing all types of reviews. Systematic reviews and meta-analyses, scoping reviews, rapid reviews, overviews, and realist reviews are only some members of review family that can benefit from using computer programs. The research, innovations, discussions, and skepticism around and surrounding the automation became so important that some of automation pioneers started International Collaboration for Automation of Systematic Reviews (ICASR) https://icasr.github.io/. The current webinar will also benefit the outcome of ICASR annual meetings.
Despite emergence and listing of hundreds of tools in Systematic Review Toolbox (http://systematicreviewtools.com/), these software programs are underused. This webinar will introduce some of these programs alongside the evidence supporting their use and will provide a guide on how to choose the program, when to use them, what are their advantages and disadvantages, and why we should use them. There are automation tools for searching, screening, extracting data, analysis, and report writing. The presentation will also discuss the reasons for underusing problem and its solutions and will justify the fact that automation of evidence synthesis is still an idealist dream and why semi-automation of evidence synthesis is more realistic horizon for in the next decades.
Sara Ullsten R&D Section Manager, Cytiva and Haiyan Hong, R&D manager of Life Sciences at Saint-GobainJun 11 20202:00 pmUTC120 mins
This Webinar is a continuation of Final Revised Version of BioPhorum Extractable Testing Recommendation Part 1
Since the first publication of BioPhorum (previously known as BPOG) Extractable Testing Recommendation in 2014, the combined team of end-users and suppliers has collaborated to examine all improvement opportunities to the original Extractable Testing Recommendation since 2017. During this webinar, the presenters will highlight all the changes to the final revised version of BioPhorum Extractable Testing Recommendation. Specifically, the output of a data review of 26 extractable data sets spanning wide varieties of single use components, which has led to the changes to be made in the original recommendation, will be presented.
The revised extractable testing recommendation will be presented to highlight:
1) How to access the final version of the Biophorum Extractable Testing recommendation and example reporting template;
2) “Data Sharing Rules of the Road” recommendations for simplifying access to the reports
3 ) Where are the extractable data report flexibilities when using BEDS templates?
To facilitate a harmonized extractable data reporting to end users, the presenters will introduce the newly designed BioPhorum Extractable Data Summary (BEDS) template. Some levels of details with regards to what specific information or format of templates are compulsory and what are flexible for supplier to tailor to their own preferences will be detailed during the webinar. How end users can gain access to these extractable summary reports from suppliers, including subsuppliers, will be addressed.
Additionally, several FAQs questions will be presented to clarify some common questions. The webinars will end with 30 minutes of a panel discussion for participants to seek clarify of all presented information.
Francis Verhoeye, Global Pilot Operations Leader at Zoetis Inc. and Benjamin Asher Senior Product Manager – BioproductionJun 15 20202:00 pmUTC90 mins
FULL TITLE: Single-Use Bioprocess Platform for Veterinary Vaccine and Biopharmaceutical Pilot-Scale Production
Presented by Francis Verhoeye, Global Pilot Operations Leader at Zoetis Inc. and Benjamin Asher Senior Product Manager – Bioproduction
•Understand the implementation journey taken to accelerate veterinary biological product development
•Identify the challenges of integrating vaccine and biopharmaceutical processes
•Learn about the single use qualification and implementation process in a multi-product facility